Cargando…

Prognostic Value of Metabolic Imaging Data of (11)C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma

SIMPLE SUMMARY: Few data are available for the use of (11)C-choline positron emission tomography/computed tomography (PET/CT) in patients with hepatocellular carcinoma (HCC). The aim of the study was to analyze the clinical impact of this metabolic imaging in patients with HCC candidates for hepatec...

Descripción completa

Detalles Bibliográficos
Autores principales: Donadon, Matteo, Lopci, Egesta, Galvanin, Jacopo, Giudici, Simone, Del Fabbro, Daniele, Lanza, Ezio, Pedicini, Vittorio, Chiti, Arturo, Torzilli, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865313/
https://www.ncbi.nlm.nih.gov/pubmed/33530520
http://dx.doi.org/10.3390/cancers13030472
_version_ 1783647816982200320
author Donadon, Matteo
Lopci, Egesta
Galvanin, Jacopo
Giudici, Simone
Del Fabbro, Daniele
Lanza, Ezio
Pedicini, Vittorio
Chiti, Arturo
Torzilli, Guido
author_facet Donadon, Matteo
Lopci, Egesta
Galvanin, Jacopo
Giudici, Simone
Del Fabbro, Daniele
Lanza, Ezio
Pedicini, Vittorio
Chiti, Arturo
Torzilli, Guido
author_sort Donadon, Matteo
collection PubMed
description SIMPLE SUMMARY: Few data are available for the use of (11)C-choline positron emission tomography/computed tomography (PET/CT) in patients with hepatocellular carcinoma (HCC). The aim of the study was to analyze the clinical impact of this metabolic imaging in patients with HCC candidates for hepatectomy. Seven parameters were recorded for PET/CT in 60 patients. The Cox regression for overall survival (OS) showed that Barcelona stages (p = 0.003) and metabolic tumor volume (MTV) (p = 0.026) were the only factors independently associated with OS and furthermore, curve analysis revealed MTV ability in predicting OS. Patients with MTV ≥ 380 had worse OS (p = 0.015). The use of (11)C-choline PET/CT allows for better prognostic refinement in patients undergoing hepatectomy for HCC: integration of such metabolic modality into HCC staging system should be considered. ABSTRACT: (11)C-choline positron emission tomography/computed tomography (PET/CT) has been used for patients with some types of tumors, but few data are available for hepatocellular carcinoma (HCC). We queried our prospective database for patients with HCC staged with (11)C-choline PET/CT to assess the clinical impact of this imaging modality. Seven parameters were recorded: maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), liver standardized uptake value (SUVliver), metabolic tumor volume (MTV), photopenic area, metabolic tumor burden (MTB = MTVxSUVmean), and SUVratio (SUVmax/SUVliver). Analysis was performed to identify parameters that could be predictors of overall survival (OS). Sixty patients were analyzed: fourteen (23%) were in stage 0-A, 37 (62%) in stage B, and 9 (15%) in stage C of the Barcelona classification. The Cox regression for OS showed that Barcelona stages (HR = 2.94; 95%CI = 1.41–4.51; p = 0.003) and MTV (HR = 2.11; 95%CI = 1.51–3.45; p = 0.026) were the only factors independently associated with OS. Receiver operating characteristics curve analysis revealed MTV ability in discriminating survival (area under the curve (AUC) = 0.77; 95%CI = 0.57–097; p < 0.001: patients with MTV ≥ 380 had worse OS (p = 0.015)). The use of (11)C-choline PET/CT allows for better prognostic refinement in patients undergoing hepatectomy for HCC. Incorporation of such modality into HCC staging system should be considered.
format Online
Article
Text
id pubmed-7865313
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78653132021-02-07 Prognostic Value of Metabolic Imaging Data of (11)C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma Donadon, Matteo Lopci, Egesta Galvanin, Jacopo Giudici, Simone Del Fabbro, Daniele Lanza, Ezio Pedicini, Vittorio Chiti, Arturo Torzilli, Guido Cancers (Basel) Article SIMPLE SUMMARY: Few data are available for the use of (11)C-choline positron emission tomography/computed tomography (PET/CT) in patients with hepatocellular carcinoma (HCC). The aim of the study was to analyze the clinical impact of this metabolic imaging in patients with HCC candidates for hepatectomy. Seven parameters were recorded for PET/CT in 60 patients. The Cox regression for overall survival (OS) showed that Barcelona stages (p = 0.003) and metabolic tumor volume (MTV) (p = 0.026) were the only factors independently associated with OS and furthermore, curve analysis revealed MTV ability in predicting OS. Patients with MTV ≥ 380 had worse OS (p = 0.015). The use of (11)C-choline PET/CT allows for better prognostic refinement in patients undergoing hepatectomy for HCC: integration of such metabolic modality into HCC staging system should be considered. ABSTRACT: (11)C-choline positron emission tomography/computed tomography (PET/CT) has been used for patients with some types of tumors, but few data are available for hepatocellular carcinoma (HCC). We queried our prospective database for patients with HCC staged with (11)C-choline PET/CT to assess the clinical impact of this imaging modality. Seven parameters were recorded: maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), liver standardized uptake value (SUVliver), metabolic tumor volume (MTV), photopenic area, metabolic tumor burden (MTB = MTVxSUVmean), and SUVratio (SUVmax/SUVliver). Analysis was performed to identify parameters that could be predictors of overall survival (OS). Sixty patients were analyzed: fourteen (23%) were in stage 0-A, 37 (62%) in stage B, and 9 (15%) in stage C of the Barcelona classification. The Cox regression for OS showed that Barcelona stages (HR = 2.94; 95%CI = 1.41–4.51; p = 0.003) and MTV (HR = 2.11; 95%CI = 1.51–3.45; p = 0.026) were the only factors independently associated with OS. Receiver operating characteristics curve analysis revealed MTV ability in discriminating survival (area under the curve (AUC) = 0.77; 95%CI = 0.57–097; p < 0.001: patients with MTV ≥ 380 had worse OS (p = 0.015)). The use of (11)C-choline PET/CT allows for better prognostic refinement in patients undergoing hepatectomy for HCC. Incorporation of such modality into HCC staging system should be considered. MDPI 2021-01-26 /pmc/articles/PMC7865313/ /pubmed/33530520 http://dx.doi.org/10.3390/cancers13030472 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Donadon, Matteo
Lopci, Egesta
Galvanin, Jacopo
Giudici, Simone
Del Fabbro, Daniele
Lanza, Ezio
Pedicini, Vittorio
Chiti, Arturo
Torzilli, Guido
Prognostic Value of Metabolic Imaging Data of (11)C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma
title Prognostic Value of Metabolic Imaging Data of (11)C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma
title_full Prognostic Value of Metabolic Imaging Data of (11)C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma
title_fullStr Prognostic Value of Metabolic Imaging Data of (11)C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma
title_full_unstemmed Prognostic Value of Metabolic Imaging Data of (11)C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma
title_short Prognostic Value of Metabolic Imaging Data of (11)C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma
title_sort prognostic value of metabolic imaging data of (11)c-choline pet/ct in patients undergoing hepatectomy for hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865313/
https://www.ncbi.nlm.nih.gov/pubmed/33530520
http://dx.doi.org/10.3390/cancers13030472
work_keys_str_mv AT donadonmatteo prognosticvalueofmetabolicimagingdataof11ccholinepetctinpatientsundergoinghepatectomyforhepatocellularcarcinoma
AT lopciegesta prognosticvalueofmetabolicimagingdataof11ccholinepetctinpatientsundergoinghepatectomyforhepatocellularcarcinoma
AT galvaninjacopo prognosticvalueofmetabolicimagingdataof11ccholinepetctinpatientsundergoinghepatectomyforhepatocellularcarcinoma
AT giudicisimone prognosticvalueofmetabolicimagingdataof11ccholinepetctinpatientsundergoinghepatectomyforhepatocellularcarcinoma
AT delfabbrodaniele prognosticvalueofmetabolicimagingdataof11ccholinepetctinpatientsundergoinghepatectomyforhepatocellularcarcinoma
AT lanzaezio prognosticvalueofmetabolicimagingdataof11ccholinepetctinpatientsundergoinghepatectomyforhepatocellularcarcinoma
AT pedicinivittorio prognosticvalueofmetabolicimagingdataof11ccholinepetctinpatientsundergoinghepatectomyforhepatocellularcarcinoma
AT chitiarturo prognosticvalueofmetabolicimagingdataof11ccholinepetctinpatientsundergoinghepatectomyforhepatocellularcarcinoma
AT torzilliguido prognosticvalueofmetabolicimagingdataof11ccholinepetctinpatientsundergoinghepatectomyforhepatocellularcarcinoma